Has real earnings that are identifiable. Could see them making $0.35US this year and growing to $0.80US next year. Market share is back again in spite of the recall troubles they experienced. Looking to diversify the stent further away from the heart.

A long term play. Expects there will be much sharper pencils on the budget going forward.

Looks a little bit expensive. Excellant company.

(A Top Pick in March/04.) Still likes. Thinks the market in tissue has bottomed out and expects stronger prices going forward. Margins in container board is improving. Book value is almost $13. Cyclical.

Would be concerned about their ability to maintain the dividend as they haven't been earning it. Trades at a fairly significant premium to book value.

Well managed company. Has had some problems with a plant in the UK, but this is getting cleared up. Profitable.

Well diversified globally. Japan's operation is now profitable and growing rapidly. Excellant management. John Hancock acquisition was a good move.